(Il Sole 24 Ore Radiocor) - Milano, 11 mag - Novo Nordisk shares were higher in Copenhagen stock market trading, after analysts at Citi and SB1 Markets raised their target prices on the Danish pharmaceutical group in the wake of strong first quarter results and due to the strong prospects for its anti-obesity drug Wegovy.

At 1000 GMT, Novo Nordisk shares were up 3.39% to 300.05 Danish crowns.

Analysts at Citi confirmed their "neutral" recommendation on the stock while raising the target price to 290 crowns from a previous 275.

Following the release of better-than-expected first quarter results on May 6, Citi said it had maintained its forecast for Novo Nordisk 2026 earnings per share but raised those for 2027-2031 by 2-3%, mainly due to higher estimates for Wegovy.

Citi forecasts a revenue of 2.7 billion dollars for Wegovy in its pill version in 2026 and expects peak sales could reach 8 billion. That compares with an analyst consensus for 2026 sales of 1.7 billion dollars and peak sales of 7.1 billion.

Meanwhile, SB1 Markets increased its Novo Nordisk target price to 350 crowns from a previous 280 and reiterated its.

"buy" recommendation on the stock.

(RADIOCOR) 11-05-26 12:07:28 (0270) 5 NNNN